Home Investors Support Phage Therapy

Investors Support Phage Therapy

Press Release: June 27, 2019

Novel Approach to Solve the Antibiotics Crisis Receives Further Millions

Vienna (Austria), 27 June 2019: Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further EUR 1.5 million in equity investments to support this novel approach to tackle the antibiotics crisis. The additional funding will be used to accelerate three in-house development programs.

PhagoMed Biopharma GmbH (PhagoMed) works on solutions for the global antibiotics crisis – the increasing rate of multi-drug resistances against the historically so effective antibiotics. The company develops pharmaceuticals based on natural viruses, called phages, that can infect and destroy bacteria. Phages and phage-based pharmaceuticals therefore have the potential to become a highly effective alternative to antibiotics for the treatment of multi-drug resistant infections. Indeed, PhagoMed’s co-founders have successfully treated individual patients with phages in Germany – as a last resort when antibiotics had failed.

Already in 2018 PhagoMed successfully raised more than EUR 4 million in public grants and private investments and set up its research programs at the Vienna Biocenter. The company today announced further investments from existing and new investors totaling EUR 1.5 million.

„Our research activities over the past year led to the identification of a series of drug candidates, the first of which are now being validated in animal trials. These results convinced both our existing and new investors to support our R&D activities with further equity investments”, says Alexander Belcredi, Co-Founder and Co-CEO of PhagoMed. „These additional seed investments will allow us to further increase the research team in Vienna and to selectively invest into our infrastructure.”

One specific field of focus for the company is the treatment of infected artificial joints, such as hip prostheses. These widespread infections are difficult to treat since they are often caused by multi-drug resistant bacteria. In addition, these bacteria typically form a biofilm on the surface of the prosthesis, which further reduces the effectiveness of antibiotics. In these types of complex infections phages are especially promising as a treatment alternative since they can degrade the bacterial biofilms as well as kill the multi-drug resistant bacteria. One of the potent drug candidates identified by PhagoMed is specifically aimed at these infections and is now being validated in animal trials. PhagoMed plans to start a first clinical trial in this indication by 2021.

About PhagoMed Biopharma GmbH
PhagoMed Biopharma GmbH is an Austrian biotech company focused on the development of human therapeutic applications of phages and phage-derived proteins. Currently, PhagoMed has three active development programs in the fields of periprosthetic joint infections, urinary tract infections and bacterial vaginosis. These development programs are based on the experiences of its clinical co-founders with last-resort treatments, as well as research collaborations with highly renowned scientists and research institutions in Germany and Belgium. Since its incorporation in November 2017, the company has raised more than €5.5 million in private investments and public grants. PhagoMed has a team of eleven highly skilled scientist working on its programs, six of which at the Campus Vienna Biocenter in Vienna, Austria.

About Phages
Phages are viruses that only infect bacteria. Phages multiply by injecting their DNA into the bacteria and reprogramming the bacterial cells to produce new phages. As soon as sufficient phages have been produced by the bacteria, the phages express special enzymes that degrade the bacterial cell wall and lead to the death of the bacterial cell. Individual phages are only active against a limited spectrum of bacteria (typically even only within one species). The combination of high selectivity as well as high effectiveness in killing bacteria makes phages highly attractive as an alternative to antibiotics for the treatment of serious bacterial infections.

Contact PhagoMed
Alexander Belcredi
PhagoMed Biopharma GmbH
Goldeggasse 6, Top 5-6
1040 Wien
E alexander.belcredi@phagomed.com
W www.phagomed.com

Copy Editing & Distribution
PR&D – Public Relations for Research & Development
Dr. Barbara Bauder
Mariannengasse 8
1090 Wien
T +43 / 1 / 505 70 44
E bauder@prd.at
W http://www.prd.at/

Notes to editors

For more information, please contact:

Visit the newsroom of: PRD